open access

Vol 13, No 4 (2018)
Heart failure
Published online: 2018-09-12
Get Citation

Heart failure — discharge management the crucial point in heart failure care

Małgorzata Lelonek
DOI: 10.5603/FC.2018.0080
·
Folia Cardiologica 2018;13(4):371-377.

open access

Vol 13, No 4 (2018)
Heart failure
Published online: 2018-09-12

Abstract

Patients after hospitalisation due to acute heart failure (HF) have higher risk of mortality and rehospitalisations, especially in the 60 to 90 days after the discharge. Every HF rehospitalisation worsens prognosis and increases risk of death in HF patients. The discharge and early phase after the discharge with treatment modified HF is crucial in prevention of HF hospitalisation. This article presents the current knowledge how to manage in the discharge period and in the early phase after the discharge from hospital.

Abstract

Patients after hospitalisation due to acute heart failure (HF) have higher risk of mortality and rehospitalisations, especially in the 60 to 90 days after the discharge. Every HF rehospitalisation worsens prognosis and increases risk of death in HF patients. The discharge and early phase after the discharge with treatment modified HF is crucial in prevention of HF hospitalisation. This article presents the current knowledge how to manage in the discharge period and in the early phase after the discharge from hospital.
Get Citation

Keywords

heart failure, discharge management

About this article
Title

Heart failure — discharge management the crucial point in heart failure care

Journal

Folia Cardiologica

Issue

Vol 13, No 4 (2018)

Pages

371-377

Published online

2018-09-12

DOI

10.5603/FC.2018.0080

Bibliographic record

Folia Cardiologica 2018;13(4):371-377.

Keywords

heart failure
discharge management

Authors

Małgorzata Lelonek

References (24)
  1. Gierczyński J, Wróblewski T, Gilewski M. Priorytety zdrowotne w kontekście demograficznego i gospodarczego rozwoju Polski. Wnioski i rekomendacje na przykładzie niewydolności serca. Raport Warsaw Enterprise Institute. Warszawa. 2018.
  2. Niewydolność serca w Polsce — raport 2016. Materiały informacyjne Sekcji Niewydolności Serca PTK. Dostępne: http://www.niewydolnosc- serca.pl/barometr.pdf. http://www.niewydolnosc-serca.pl/barometr.pdf (15.07.2018).
  3. Karczewicz E, Zalewska H. Niewydolność serca — analiza kosztów ekonomicznych i społecznych. Raport badawczy [online]. Warszawa 2013. , Warszawa 2013.
  4. Solomon SD, Dobson J, Pocock S, et al. Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Investigators. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007; 116(13): 1482–1487.
  5. Yilmaz MB. A. Mebazaa. Definition and characteristics of the vulnerable phase in heart failure. Medicographia. 2015; 37: 139–143.
  6. Matyjas K, Lelonek M. Pacjent z niewydolnością serca w okresie vulnerable phase. Folia Cardiol. 2018; 13(1): 71–78.
  7. Mebazaa A, Yilmaz MB, Levy P, et al. Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail. 2015; 17(6): 544–558.
  8. Mueller C, Christ M, Cowie M, et al. Acute Heart Failure Study Group of the ESC Acute Cardiovascular Care Association. European Society of Cardiology-Acute Cardiovascular Care Association Position paper on acute heart failure: A call for interdisciplinary care. Eur Heart J Acute Cardiovasc Care. 2017; 6(1): 81–86.
  9. Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force Members, Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016; 18(8): 891–975.
  10. DeVore AD, Mi X, Mentz RJ, et al. Discharge heart rate and β-blocker dose in patients hospitalized with heart failure: findings from the OPTIMIZE-HF registry. Am Heart J. 2016; 173: 172–178.
  11. Hidalgo FJ, Anguita M, Castillo JC, et al. Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): A randomised study. Int J Cardiol. 2016; 217: 7–11.
  12. Lopatin YM, Cowie MR, Grebennikova AA, et al. Optimization of heart rate lowering therapy in hospitalized patients with heart failure: Insights from the Optimize Heart Failure Care Program. Int J Cardiol. 2018; 260: 113–117.
  13. Ryan J, Kang S, Dolacky S, et al. Change in readmissions and follow-up visits as part of a heart failure readmission quality improvement initiative. Am J Med. 2013; 126(11): 989–994.e1.
  14. Bradley EH, Sipsma H, Horwitz LI, et al. Hospital strategy uptake and reductions in unplanned readmission rates for patients with heart failure: a prospective study. J Gen Intern Med. 2015; 30(5): 605–611.
  15. Metra M, Gheorghiade M, Bonow RO, et al. Postdischarge assessment after a heart failure hospitalization: the next step forward. Circulation. 2010; 122(18): 1782–1785.
  16. Opolski G, Ozierański K, Lelonek M, et al. Adherence to the guidelines on the management of systolic heart failure in ambulatory care in Poland. Data from the international QUALIFY survey. Pol Arch Intern Med. 2017; 127(10): 657–665.
  17. Lelonek M. Niewydolności serca z obniżoną frakcją wyrzutową lewej komory — jakich informacji dostarczył rejestr QUALIFY? Folia Cardiol. 2018; 13(3): 259–262.
  18. Swedberg K, Komajda M, Böhm M, et al. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010; 376(9744): 875–885.
  19. Böhm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013; 102(1): 11–22.
  20. Greene SJ, Vaduganathan M, Wilcox JE, et al. EVEREST Trial Investigators. The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. JACC Heart Fail. 2013; 1(6): 488–496.
  21. Borer JS, Böhm M, Ford I, et al. SHIFT Investigators. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J. 2012; 33(22): 2813–2820.
  22. Fonarow GC, Abraham WT, Albert NM, et al. Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). Am J Cardiol. 2008; 102(11): 1524–1529.
  23. McMurray JJV, Packer M, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11): 993–1004.
  24. Komajda M, Cowie MR, Tavazzi L, et al. QUALIFY Investigators. Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail. 2017; 19(11): 1414–1423.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl